Altered Expression of Fibronectin and Collagens I and IV in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance
Overview
Affiliations
Multiple myeloma (MM) is an incurable B-cell malignancy that arises in the bone marrow (BM). The malignant cells within the BM have extensive interaction with the structural components of their microenvironment. It has been previously shown that the interactions between MM cells and the BM extracellular matrix (ECM) proteins contribute to drug resistance. To understand the underlying causes of adhesion-mediated drug resistance in MM, the components of human BM ECM available for interactions with MM cells must be characterized. We analyzed the expression and localization of fibronectin, laminin, and collagens I and IV in the core biopsies of normal donors and patients with monoclonal gammopathy of undetermined significance (MGUS) or MM. In addition, we compared the patterns of ECM expression in MM patients with low-, mid-, and high-level plasmacytosis of the BM. Although expression of laminin was the same for all groups tested, levels of fibronectin and collagen I were reduced in MM patients with high-level plasmacytosis. Expression of collagen IV in the BM of MGUS and MM patients was higher than in the BM from normal donors. Compared with the plasma cells isolated from the patients with low- and mid-level plasmacytosis, sorted CD138(+) plasma cells from MM patients with high-level plasmacytosis overexpressed collagen IV. Our findings show that, compared with normal controls, the ECM composition of the bone, endosteum, and BM is aberrant in patients with MM, further establishing ECM as a key player in the MM disease process.
In Vitro 3D Models of Haematological Malignancies: Current Trends and the Road Ahead?.
Mattioda C, Voena C, Ciardelli G, Mattu C Cells. 2025; 14(1.
PMID: 39791739 PMC: 11720277. DOI: 10.3390/cells14010038.
Multiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential.
Veryaskina Y, Titov S, Skvortsova N, Kovynev I, Antonenko O, Demakov S Int J Mol Sci. 2025; 25(24.
PMID: 39769169 PMC: 11679576. DOI: 10.3390/ijms252413404.
Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.
Sharma N, Choudhary B Biomolecules. 2023; 13(11).
PMID: 38002311 PMC: 10669790. DOI: 10.3390/biom13111629.
Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review.
Ismail N, Mussa A, Al-Khreisat M, Yusoff S, Husin A, Johan M Diagnostics (Basel). 2023; 13(14).
PMID: 37510072 PMC: 10378430. DOI: 10.3390/diagnostics13142328.
Platelet lysate can support the development of a 3D-engineered skin for clinical application.
Banakh I, Rahman M, Arellano C, Marks D, Mukherjee S, Gargett C Cell Tissue Res. 2022; 391(1):173-188.
PMID: 36271300 PMC: 9839813. DOI: 10.1007/s00441-022-03698-7.